Clinical Trials Sponsored by Aligos Therapeutics

Total 6424 results

Aligos Therapeutics

Recruiting

A Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558

COVID-19

United Kingdom
Aligos Therapeutics

Terminated

A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects

Chronic Hepatitis B

New Zealand, Bulgaria, Moldova, Republic of, Romania
Aligos Therapeutics

Completed

A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia

NASH - Nonalcoholic Steatohepatitis

France
Aligos Therapeutics

Terminated

A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects

Chronic Hepatitis B

United Kingdom, New Zealand
Aligos Therapeutics

Recruiting

ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) (HERALD)

Nonalcoholic Steatohepatitis | NASH | MASH | Metabolic Dysfunction-Associated Steatohepatitis

United States
Aligos Therapeutics

Recruiting

A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Chronic Hepatitis B

Hong Kong, China, United Kingdom, Moldova, Republic of, New Zealand, Australia, Mauritius
Aligos Therapeutics

Active, not recruiting

A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)

Healthy Volunteers

United States
Aligos Therapeutics

Terminated

A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Chronic Hepatitis B

Korea, Republic of, China, Hong Kong, United Kingdom, New Zealand, Moldova, Republic of
Argos Therapeutics

Terminated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

Israel, Spain, United States, Czechia, Canada, Italy, Hungary, United Kingdom
Argos Therapeutics

Completed

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

HIV Infection

United States, Canada
Argos Therapeutics

Terminated

A Rollover Protocol for Subjects Previously Treated With AGS-003

Renal Cell Carcinoma

United States
Argos Therapeutics

Completed

Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

Renal Cell Carcinoma

United States, Canada
Argos Therapeutics

Completed

RNA-Loaded Dendritic Cell Cancer Vaccine

Renal Cell Carcinoma

United States, Canada
Argos Therapeutics

Completed

Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC

Kidney Cancer | Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

United States
Argos Therapeutics

Completed

Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer

Renal Cell Carcinoma

Canada, United States
Argos Therapeutics

Completed

A Single-Patient Study Using AGS 006

Pancreatic Cancer

United States
Argos Therapeutics

Completed

Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV

HIV Infections

Canada, United States
Argos Therapeutics

Completed

An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)

Inflammation | Systemic Lupus Erythematosus (SLE)

United States
Elios Therapeutics, LLC
LumaBridge

Recruiting

Autologous TLPO Vaccine Basket

Cancer | Tumor | Tumor, Solid | Tumor Metastasis

United States
Elios Therapeutics, LLC
LumaBridge

Completed

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

Metastatic Melanoma

United States
Duke University
Argos Therapeutics

Terminated

RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)

Metastatic Renal Cell Carcinoma | Genitourinary Cancer (Bladder, Prostate or Testicular)

United States
Cancer Insight, LLC
Elios Therapeutics, LLC

Completed

Phase IIB TL + YCWP + DC in Melanoma

Melanoma

United States
Alios Biopharma Inc.

Completed

A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Moldova, Republic of, New Zealand, Thailand, Ukraine
Alios Biopharma Inc.

Completed

Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers

Respiratory Syncytial Virus Infections

France
Alios Biopharma Inc.

Terminated

A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection

Hepatitis C

Belgium
Alios Biopharma Inc.

Withdrawn

A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects

Hepatitis B, Chronic
Alios Biopharma Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir

Chronic Hepatitis C

New Zealand, Moldova, Republic of, Mauritius, United Kingdom
Alios Biopharma Inc.

Completed

A Study of ALS-008176 in Infants Hospitalized With RSV

Respiratory Syncytial Virus Infections

United States, Taiwan, Australia, Canada, United Kingdom, Colombia, France, New Zealand, Japan, South Africa, Chile, Panama, Romania, Thailand
Alios Biopharma Inc.

Completed

A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

Influenza in Humans

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176

Respiratory Syncytial Virus Infections

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus

Respiratory Syncytial Virus Infections

Australia, Singapore, United States, New Zealand, Taiwan
Alios Biopharma Inc.

Completed

A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study

Influenza

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model

Respiratory Syncytial Virus Infections

United Kingdom
Alios Biopharma Inc.

Completed

First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Chronic Hepatitis C

France, Moldova, Republic of, Georgia
Alios Biopharma Inc.

Completed

A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants

Hepatitis B

New Zealand
Alios Biopharma Inc.

Terminated

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers

Healthy

United Kingdom
Alios Biopharma Inc.

Terminated

Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

Hepatitis B | Chronic Hepatitis B | Viral Hepatitis B

New Zealand
Alios Biopharma Inc.

Completed

A Study to Assess the PK of AL-794 Formulations in Healthy Subjects

Influenza

United Kingdom
Alios Biopharma Inc.
Alexion

Completed

A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers

Chronic Hepatitis C

France
Algos Clinical Development Thomas L. Yearwood,...

Terminated

Sub-Sensory Intraspinal Neurostimulation Therapy

Back Pain | Back Pain With Radiation | Pain in Leg, Unspecified

United States
Alios Biopharma Inc.
Janssen Pharmaceutica

Terminated

First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C

Chronic Hepatitits C

Georgia, Moldova, Republic of, France
Los Amigos Research and Education Institute

Unknown

SMART (School-aged Children Making Healthy Choices And Recognizing sTroke) (SMART)

Stroke
Clinica Olivos SMG

Not yet recruiting

Airway Occlusion Measured During Non-invasive Ventilation to Assess Respiratory Effort

Healthy Volunteers

Argentina
Alios Biopharma Inc.
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Chronic Hepatitis C

Moldova, Republic of
Alios Biopharma Inc.
Vertex Pharmaceuticals Incorporated

Terminated

First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Australia, New Zealand
Lagos State University
University of Lagos, Nigeria

Recruiting

The Effect of Collagen Matrix Graft on Postoperative Palatal Fistula Formation After Cleft Palate Repair

Cleft Palate | Cleft Lip and Cleft Palate | Cleft Lip, Cleft Alveolus and Cleft Palate

Nigeria
Institute of Technology, Sligo
Sligo General Hospital

Completed

Mirror Aided Cross Education in Post Stroke Upper Limb Rehabilitation.

Stroke

Ireland
Institute of Technology, Sligo
Sligo General Hospital

Unknown

Using an Adjustable Compression Garment for Secondary Upper Limb Lymphoedema

Lymphedema of Upper Arm
Alios Biopharma Inc.
Vertex Pharmaceuticals Incorporated

Completed

First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Moldova, Republic of, Romania, France
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States

3

Subscribe